Rapport Therapeutics (RAPP) moved into focus after reporting that lead candidate RAP-219 met its primary endpoint in a Phase 2 trial for acute bipolar I mania, with statistically significant efficacy and a favorable tolerability profile.
Rapport Therapeutics' latest update landed after a choppy stretch. The 1-day share price return of 5.9% contrasts with a 7-day move that declined 10.3% and a 30-day share price return that fell 36.0%, even though the 1-year total shareholder return is still positive at 1.3%.
Spot fresh CNS opportunities by lining up Rapport Therapeutics against a curated field of 36 healthcare AI stocks that are riding similar clinical and neurology-focused catalysts.
Rapport Therapeutics now trades at a steep discount to analyst targets after the RAP-219 update, yet recent price weakness signals caution. Is the gap a valuation opportunity, or a warning about clinical and execution risk?
Most Popular Narrative: 62% Undervalued
At a last close of $26.53 against a narrative fair value of $69.06, Rapport Therapeutics screens as heavily discounted. That gap hinges on how investors weigh RAP-219's bipolar mania potential against clinical and safety questions.
Expansion of RAP-219 from epilepsy into acute bipolar mania through the pivotal like Phase 2 study, with topline data guided for October 2026, creates a second potential use for the same asset that could broaden future revenue streams. This may help spread fixed R&D costs, which would support margins if successful.
See why 1 investors see Rapport Therapeutics as 62% undervalued .
Result: Fair Value of $69.06 (UNDERVALUED)
Still, the RAP-219 epilepsy and bipolar programs carry clear risk, and any safety setbacks or cash runway pressure could quickly challenge the current view that the stock is undervalued.
Find out about the key risks to this Rapport Therapeutics narrative .
Another View: What Multiples Say About Rapport Therapeutics
There is one big catch in that 62% undervalued narrative for Rapport Therapeutics. On a simple P/B lens, the stock trades at about 3x book value compared with roughly 1.8x for the broader US Pharmaceuticals group, even though the business is loss making and not forecast to turn profitable in the next 3 years.
That richer ratio relative to the sector suggests the market already prices in meaningful success for RAP-219. As a result, the risk for investors is that any stumble in epilepsy or bipolar mania trials could compress that premium far faster than an upside rerating plays out.
For a closer look at how the current P/B premium stacks up to peers and what the fair ratio might imply if sentiment cools or strengthens, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed messages in the Rapport Therapeutics story so far. Act while the data is fresh and weigh both sides through the 1 key reward and 2 important warning signs .
Looking for more investment ideas beyond Rapport Therapeutics?
Broaden your watchlist with a few targeted screens that surface different types of opportunities so you are not relying on just one clinical catalyst.
-
Target deep value setups by scanning a curated pool of 29 high quality undervalued stocks that pair quality fundamentals with compressed valuations.
-
Prioritise resilience by running a filter across a list of solid balance sheet and fundamentals (26 results) so cash and debt profiles work in your favour, not against you.
-
Get ahead of the crowd by spotting 20 high quality undiscovered gems that already show strong metrics before wider market attention arrives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include RAPP .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
